Silverberg Bernstein Capital Management LLC Sells 2,720 Shares of ChromaDex Co. (NASDAQ:CDXC)

Silverberg Bernstein Capital Management LLC lowered its position in shares of ChromaDex Co. (NASDAQ:CDXC) by 3.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 80,537 shares of the company’s stock after selling 2,720 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.11% of ChromaDex worth $427,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BSW Wealth Partners purchased a new stake in shares of ChromaDex during the third quarter valued at approximately $324,000. WINTON GROUP Ltd purchased a new stake in shares of ChromaDex during the 2nd quarter valued at $597,000. FMR LLC bought a new stake in shares of ChromaDex during the 3rd quarter worth $55,000. State Street Corp boosted its holdings in shares of ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after buying an additional 62,692 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in ChromaDex by 1.6% during the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock valued at $4,197,000 after buying an additional 17,963 shares during the period. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Insiders Place Their Bets

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 9.64% of the company’s stock.

ChromaDex Stock Performance

NASDAQ:CDXC opened at $5.66 on Wednesday. The firm has a market cap of $432.33 million, a price-to-earnings ratio of 566.57 and a beta of 2.21. ChromaDex Co. has a 52-week low of $1.36 and a 52-week high of $7.97. The business’s fifty day moving average is $6.40 and its 200 day moving average is $4.40.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The firm had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. During the same quarter last year, the firm posted ($0.01) EPS. Equities analysts predict that ChromaDex Co. will post 0.04 EPS for the current fiscal year.

Analyst Ratings Changes

CDXC has been the topic of several research reports. Roth Mkm lifted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Finally, StockNews.com lowered ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.